Key Takeaways Eli Lilly signed a deal worth up to $2.75B with Insilico for AI-driven drug discovery rights.LLY is integrating AI across R&D, using platforms to speed drug discovery and cut timelines. Healthcare ETFs like IHE offer diversified exposure to AI-focused pharma leaders. U.S. pharma giant Eli Lilly (LLY) has just thrust the rapidly evolving field of artificial intelligence (AI)-driven drug discovery into the spotlight, signing a landmark deal worth up to $2.75 billion with Hong Kong-based Insilico ...

Eli Lilly (NYSE: LLY) is a leading healthcare company that has been generating some incredible results in recent years. It has some excellent GLP-1 drugs in its portfolio -- Zepbound and Mounjaro -- which are in high demand from patients looking to lose weight and become healthier. The knock on the stock these days, however, is that it may have gotten too expensive, and that demand may also slow down in the future. As a result, shares of Eli Lilly haven't been all that hot of late. Instead, they've been in ...

Fed Officials Warn on Inflation, Job Market Outlook The Iran War Has Shaken Up Asset Prices The War Is Crushing Consumer Sentiment Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership Stocks Plunge, Oil Surges Top Stories Eli Lilly shares are down nearly 20% since the start of the year. Mark Felix / Bloomberg / Getty Images Close Key Takeaways Eli Lilly is doubling down on AI drug development with its latest deal. Eli Lilly (LLY) is expanding its partnership with Ins ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Bristol Gate Capital Partners, an investment management company, published its Q4 2025 investor letter for the “US Equity Strategy”. A copy of the letter can be downloaded here. Bristol Gate prioritizes companies with strong free cash flows, disciplined capital allocation, and high dividend growth for superior risk-adjusted returns. These resilient businesses align management interests with shareholders through sustainable dividends. Since late 2022, the market has shifted towards AI leaders, resulting in t ...

Lilly will obtain exclusive rights to sell treatments discovered using InSilico's Pharma.AI model. ...

Pharmaceutical titan Eli Lilly wants to bring medications developed with AI to market.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.To that end, the company has struck a $2.75 billion deal, announced Sunday (Marc ...

Eli Lilly and Company (NYSE:LLY) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Eli Lilly and Company (NYSE:LLY) is the premier player in the weight loss drug industry. Its shares are up by 6% over the past year and by 21% since Cramer discussed them in January 2025. They closed 8% higher on October 1st, on the day it surfaced that the Trump administration would give pharmaceutical giant Pfizer a three-year grace from tariffs. Eli Lilly and Company (NYSE:LLY)’s shares then proceeded to ...

整理 | GLP1减重宝典内容团队 市场最近盯上的，正是礼来的口服GLP-1药物 orforglipron。更准确地说，它不是已经确定会在4月正式开卖，而是审批窗口已经逼近。 礼来自己的公开表述是，这款药针对肥胖或超重适应症的美国监管结果有望在2026年第二季度出炉，市场普遍关注的时间点集中在4月 上旬。礼来管理层同时表示，公司正按二季度上市的节奏做准备。 如果这张牌顺利落地，最先感到疼的，不会是整个司美格鲁肽市场同时被掀翻，而是口服司美格鲁肽先被正面撞上。礼来披露， orforglipron 是一款每日一次的小分子口服GLP-1，可以不受进食和饮水限制服用；相比之下，诺和诺德现有的 Rybelsus 和 Wegovy 片 剂都要求晨起空腹、以少量清水送服，并至少等待30分钟后才能进食、饮水或服用其他口服药。对真实世界依从性来说，这不是小差 别，而是会直接影响患者能不能长期坚持。 数据层面，礼来也已经把矛头直接对准了口服司美格鲁肽。在一项头对头Ⅲ期研究中，orforglipron 36 mg 在2型糖尿病患者中的糖化血 红蛋白降幅达到2.2%，口服司美格鲁肽14 mg为1.4%；体重降幅分别为9.2%和5.3 ...

礼来在中国减重赛道又落下一子，但这一次主角并不是传统意义上的GLP-1。公开信息显示，礼来新型长效减重候选药 Eloralintide 已获中国 国家药监局药品审评中心批准，进入中国Ⅲ期临床，并将同步参与多项全球关键注册研究，目标直指成人体重管理市场。不过也要看到， Eloralintide 目前仍是一款研究中药物，尚未在中国或美国正式获批上市。 这次推进到中国的关键研究，基本覆盖了 Eloralintide 最重要的减重应用场景。一项研究主要针对未合并2型糖尿病的肥胖或超重成人，另一项 聚焦合并2型糖尿病的肥胖或超重人群，还有一项则瞄准已经接受稳定肠促胰素类治疗、但减重效果仍不理想的持续性肥胖或超重患者。这样的 布局很清楚，礼来并不是把这款药当作单一补充品种来推进，而是在为更广泛的人群适应证和未来联合治疗路径提前铺路。 Eloralintide 最值得注意的地方，在于它不是一款新的GLP-1药物，而是一款每周一次给药的选择性胰淀素受体激动剂。胰淀素这条路线近两年 重新升温，背后的逻辑并不复杂。减重药市场经过几轮洗牌之后，行业已经越来越清楚，下一阶段竞争不只是比谁减得更多，也要比谁机制更 新、耐受性更好、适用 ...